The EBIN phase 2 trial evaluated whether targeted therapy induction followed by immunotherapy is superior to immunotherapy alone in advanced BRAFV600-mutant melanoma.
No significant difference in progression-free survival (PFS) was observed between the two strategies.
The induction group experienced higher rates of severe (grade 3-5) treatment-related adverse events.
Current data do not support routine use of targeted therapy induction in unselected patients with BRAFV600-mutant metastatic melanoma.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.